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treatment of coronary artery disease (CAD). METHOD: In 
this prospective comparative cohort study in 30 hospitals in
Germany, patients with coronary artery disease (CAD) undergo-
ing PTCA were electively treated with drug-eluting stents (DES)
or bare-metal stents (BMS). Standardized questionnaires com-
pleted by patients and physicians at 3, 6, 12, and 18 months 
following PTCA documented major adverse coronary events
(MACE), including death, myocardial infarct, coronary bypass
surgery and reintervention as well as direct and indirect costs
related to CAD. Patient health-related and disease-speciﬁc
quality of life was documented with the SF-36 and MacNew
heart disease questionnaires. RESULTS: From April until August
2004, 237 patients were treated with DES (88% male, mean age
63 ± 10) und 241 patients with BMS (82% male, mean age 65
± 10). There were no signiﬁcant differences in socio-demographic
factors, cardiovascular risk factors and severity of CAD. After 6
months, 11.6% of the DES cohort and 26.7% of the BMS cohort
had suffered a MACE (p < 0.05). The quality of life (SF-36 phys-
ical and mental summary scores and MacNew global score) at 3
months was higher in the DES cohort than in the BMS cohort
but at 6 months, both groups were similar. Initial hospital costs
were signiﬁcantly higher for DES than for BMS (6290 ± 1800
vs. 3655 ± 541 €, p < 0.001). The 6-month follow-up costs of
DES tended to be less than those of BMS (4305 ± 6031 vs. 5873
± 6442 €, p = n.s.). CONCLUSIONS: In comparison to patients
following BMS implantation, patients 6 months following
implantation of a DES have considerably fewer clinically rele-
vant adverse events, while the quality of life at this time point
was similar in both cohorts. Initial hospital costs were signiﬁ-
cantly higher for DES than for BMS but 6-month follow-up costs
were less for DES.
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OBJECTIVES: To estimate the economic burden of coded post-
operative ileus (POI) among patients undergoing open laparo-
tomies in the US. METHODS: Using Premier’s PerspectiveTM
database, we identiﬁed 193,409 open laparotomy surgical
patients based on their primary discharge ICD-9 procedure code
during 2002. Coded POI was identiﬁed using ICD-9 diagnosis
codes 560.1 and 997.4. Risk factors for coded POI were ana-
lyzed by a logistic regression model. To assess the economic
burden of coded POI, multiple regression analyses were per-
formed predicting hospital length of stay and total hospital costs
while controlling for baseline variables. Estimates of incremen-
tal costs and length of hospital stay were projected to the
national level. RESULTS: Extended operating room time
increased the risk of coded POI by 20% for each one-hour
increase (OR, 1.20, 95% CI, 1.19–1.21). Mean operating room
time was 3.0 ± 1.7 hours for patients with coded POI versus 2.5
± 1.2 hours for patients without coded POI. Use of PCA opioids
increased the risk of coded POI by 39% (OR, 1.39, 95% CI,
1.34–1.44). Coded POI was associated with an additional 2.6
days (P < 0.01) in the hospital and $1763 (P < 0.01) in total 
hospital costs. For the US, the overall burden of coded POI for
open laparotomies was estimated to be an additional 370,000
days in the hospital and $253 million in total costs. CONCLU-
SIONS: POI is associated with a signiﬁcant economic impact.
Inpatients with coded POI have extended operating time and
increased use of PCA opioids. POI was also associated with
increased hospital stay and consequently, hospital costs. Since
POI may not be routinely coded in this database, the true eco-
nomic burden of POI may be underestimated. Strategies to
reduce the impact of POI should lead to economic savings to the
hospital system.
PSU2
ELECTIVE SURGERIES IN THE US: RISK FACTORS, COST,
AND OUTCOMES
Saunders WB,Wang PF, Gaylord B
Premier, Inc, Charlotte, NC, USA
OBJECTIVE: To determine the impact of age and gender on the
frequency and resource utilization among inpatients with a claim
for an elective surgery between October 2003 and September
2004 in the Premier Perspective Database. METHODS: All inpa-
tient and outpatient discharges with a claim for one of ﬁve elec-
tive surgeries between October 2003 and September 2004 were
retrieved. Procedures of interest were botox injections (botu-
linum toxin), liposuction (lipoplasty or lipectomy), nose reshap-
ing (rhinoplasty), breast augmentation (mammoplasty), and laser
treatment of leg veins (schlerotherapy or sclerosing). The rela-
tionship between each surgery and age, gender, length of stay,
and costs was examined, and the distinction between “elective”
and “necessary” surgeries is made where possible. RESULTS:
Overall, there were 2349 claims for botox injections (among
inpatients, 56% female; among outpatients, 62% female), 189
liposection procedures (over 91% females), 261 nose reshaping
procedures (55% male), 293 breast augmentations (over 96%
females), and 8,635 treatments of leg veins (among inpatients,
45% female; among outpatients, 50% female). With the excep-
tion of leg vein procedures, most were performed in hospital-
based outpatient clinics. Most botox procedures were performed
on females in outpatient clinic settings (n = 1177), and 9% were
performed on teens. Most liposection procedures were among
19–44 year-old females (57%) and middle-aged females (39%)
seen in outpatient clinics. In addition, most nose reshaping (more
common in males and teenagers received 10% of these proce-
dures) and breast augmentations occurred in the outpatient
setting (3% were among teens). Finally, most leg vein procedures
were among elderly inpatients, many of these non-elective surg-
eries. Additional results regarding the medications used, as well
as readmission, will be presented. CONCLUSION: Elective surg-
eries are common, and are captured in administrative hospital
data. Further research using data from specialty clinics should
be performed to better understand the magnitude and health
impacts associated with these procedures.
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OBJECTIVES: Numerous prescription products have become
available OTC in recent years and there are several reasons why
this number is likely to increase signiﬁcantly in the future. To
date, there have been simulation models, but no empirical assess-
ment of the impact of the Rx-to-OTC switch of loratadine. Pre-
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vious simulation models have shown the Rx-to-OTC switch of
loratadine to be cost-effective. The purpose of this research is to
empirically assess the overall impact of the Rx-to-OTC switch
of loratadine as well as the speciﬁc impact of different pharmacy
beneﬁt structures on prescription drug utilization and cost in a
variety of plan sponsors. METHODS: Data from a national
pharmacy beneﬁt management organization covering 27 million
lives throughout the US were used. The analysis included a com-
parison of the difference in prescription utilization and cost for
the 12-months after a change in prescription beneﬁts for second-
generation antihistamines (SGA) due to OTC loratadine com-
pared to 12-months before for plan sponsors that instituted no
change, moved SGA to the 3rd-tier and restricted SGA beneﬁts
through prior authorization requirement. Change in utilization
and cost of medications for allergic rhinitis (AR), asthma, respi-
ratory infections and all classes combined was examined. Mul-
tivariate regression analysis was used to control for differences
across study groups. RESULTS: There was a substantial decrease
in utilization and cost of all prescription drugs and combinations
of drug classes. AR patients facing restricted prescription bene-
ﬁts for SGA did not appear to increase utilization of other AR
medications or other medications used to treat comorbid condi-
tions such as asthma, sinusitis and otitis media. CONCLU-
SIONS: Utilization and cost decreased substantially for all types
of medications and all pharmacy beneﬁt structures. Future
studies need to examine the impact of the Rx-to-OTC switch of
loratadine and resultant prescription beneﬁt policies on medical
utilization and OTC antihistamine utilization.
PAL2
PATIENT PERCEPTIONS REGARDING THE USE OF OVER-
THE-COUNTER CLARITIN
Nair KV, Sullivan P
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OBJECTIVE: To examine patient perceptions regarding medica-
tion efﬁcacy, safety and cost of using over-the-counter (OTC)
Claritin and its impact on work related productivity.
METHODS: A web-based survey was administered to employ-
ees of a large University via a voluntary-based e-mail list. Survey
items included the choice of medication used by individuals prior
to and following the availability of OTC Claritin, perceptions of
efﬁcacy, symptom control, cost and safety of OTC Claritin as
well perceptions of work related productivity. Bivariate compar-
isons using chi square analysis were used to describe the study
results. RESULTS: Sample consisted of 221 respondents of which
19% were either taking a prescription medication or nasal spray,
other OTC medications, both a prescription and OTC medica-
tion, allergy shots, herbal medications or who were not treating
their allergies prior to the availability of OTC Claritin switched
to OTC Claritin. Older individuals were less likely to switch to
OTC Claritin. Half the individuals who switched from prescrip-
tion medication to OTC Claritin reported having better control
of their allergic rhinitis symptoms (p < 0.05). In total, 88% of
these individuals reported no difference in side effects between
their prescription medication and OTC Claritin, while 82%
reported that OTC Claritin was more expensive than their prior
prescription medication (p < 0.05). However, only 28% of these
individuals reported their allergy symptoms did not interfere at
all with their work while taking OTC Claritin, while 38%
reported that they were only between 60–80% as productive at
work when taking OTC Claritin. CONCLUSIONS: Preliminary
results suggest that the adoption of OTC Claritin may not be as
widespread as anticipated. While patients’ report equal or better
symptom control with OTC Claritin, self reports of work related
productivity do not appear to corroborate these ﬁndings. Further
research is needed to examine the indirect impact of OTC Clar-
itin on presenteism and absenteeism.
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OBJECTIVES: Patients’ willingness to pay (WTP) for intranasal
corticosteroid (INS) products was evaluated. METHODS: One
hundred twenty patients with allergic rhinitis were recruited
from four US allergy/immunology clinics. Participants chose
between hypothetical INSs differing in degree across six attrib-
utes (smell, taste, aftertaste, throat rundown, nose runout, and
feel of spray) and monthly co-pays ($15, $30, and $50). Attrib-
utes were deﬁned in three levels (strong, weak, and none).
Strength of preference was measured as marginal WTP to avoid
higher-degree levels. RESULTS: Patients were willing to pay $11
(95% conﬁdence interval [CI]: $9 to $13) per month to avoid
strong smell over no smell, $12 (95% CI: $10 to $14) to avoid
strong taste over no taste, $20 (95% CI: $18 to $22) to 
avoid strong aftertaste over no aftertaste, $10 (95% CI: $9 to
$12) to avoid excess throat rundown over no throat rundown,
$11 (95% CI: $9 to $13) to avoid excess nose runout over no
nose runout, and $6 (95% CI: $4 to $8) per month to avoid dry
spray over moist spray. When moderate to low levels were com-
pared, aftertaste, throat rundown, and nose runout were still
associated with a signiﬁcant WTP. Income level was not associ-
ated with changes in WTP except for throat rundown. Patients
with an income >$80,000 were willing to pay more to avoid
excess throat rundown than those with an income <$0,000.
CONCLUSIONS: Patients are willing to pay for an INS with
favorable sensory attributes.
ARTHRITIS—Osteoarthritis
PAR1
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OBJECTIVE: In September, 2004, rofecoxib was withdrawn
from the market due to cardiovascular safety concerns, and con-
cerns have been raised about the cardiovascular safety of other
Cox-2s. This study identiﬁes the characteristics of Cox-2 users
in the six months preceding rofecoxib withdrawal and tracks the
NSAID utilization of this cohort by cardiovascular risk and other
characteristics. METHODS: Pharmacy claims from a large,
private pharmacy beneﬁt management ﬁrm were analyzed. Indi-
viduals with a claim for any Cox-2 inhibitor in the 180 days
prior to rofecoxib withdrawal were identiﬁed, and their cardio-
vascular risk assessed on a surrogate measure based on pharmacy
claims. Subsequent NSAID utilization of this cohort was tracked
through December, 2004 and through mid-2005. RESULTS:
Over 130,000 Cox-2 users were identiﬁed in the six months prior
to rofecoxib withdrawal. Thirty-four percent were male, 31%
age 65 or older, and 31% had a pharmaceutical marker sug-
gesting cardiovascular risk. In the three months following rofe-
coxib withdrawal, 50% of Cox-2 users had a claim for an
NSAID (Cox-2 or non-selective NSAID), and individuals with
CV risk were more likely than those at lower risk to have an
NSAID claim (57% vs. 47%, p < 0.0001). Of those with an
